Australia - Kiingereza - APVMA (Australian Pesticides and Veterinary Medicines Authority)

syngenta australia pty ltd - fludioxonil; metalaxyl-m; azoxystrobin - suspension concentrates for seed treatment (fs) - fludioxonil phenylpyrrole active 12.5 g/l; metalaxyl-m phenylamide active 37.5 g/l; azoxystrobin pyrimidine active 75.0 g/l - fungicide - cotton - damping off - rhizoctonia spp. | pythium spp. | rhizoctonia | grease spot | pythium blight | soil fungi

Australia - Kiingereza - APVMA (Australian Pesticides and Veterinary Medicines Authority)

syngenta australia pty ltd - metalaxyl-m; sedaxane; thiamethoxam; difenoconazole - suspension concentrates for seed treatment (fs) - metalaxyl-m phenylamide active 9.5 g/l; sedaxane pyrazole active 8.0 g/l; thiamethoxam thiazole active 30.7 g/l; difenoconazole triazole active 36.9 g/l - fungicide

Australia - Kiingereza - APVMA (Australian Pesticides and Veterinary Medicines Authority)

nufarm australia limited - fipronil - suspension concentrates for seed treatment (fs) - fipronil nitrile active 500.0 g/l - insecticide

Australia - Kiingereza - APVMA (Australian Pesticides and Veterinary Medicines Authority)

abbey laboratories pty ltd - toltrazuril - oral solution/suspension - toltrazuril antiprotozoal-coccidiostat active 50.0 g/l - parasiticides

Australia - Kiingereza - APVMA (Australian Pesticides and Veterinary Medicines Authority)

nufarm australia limited - imidacloprid; metalaxyl-m; flutriafol - suspension concentrates for seed treatment (fs) - imidacloprid guanidine active 180.0 g/l; metalaxyl-m phenylamide active 15.0 g/l; flutriafol triazole active 6.25 g/l - mixed function seed treat

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - irbesartan, quantity: 300 mg; hydrochlorothiazide, quantity: 25 mg - tablet, film coated - excipient ingredients: lactose monohydrate; povidone; croscarmellose sodium; magnesium stearate; iron oxide yellow; iron oxide red; titanium dioxide; hypromellose; macrogol 4000; iron oxide black - for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - irbesartan, quantity: 300 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet, film coated - excipient ingredients: lactose monohydrate; povidone; magnesium stearate; croscarmellose sodium; iron oxide yellow; iron oxide red; titanium dioxide; hypromellose; macrogol 4000 - for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - irbesartan, quantity: 150 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet, film coated - excipient ingredients: magnesium stearate; povidone; lactose monohydrate; croscarmellose sodium; iron oxide yellow; iron oxide red; titanium dioxide; hypromellose; macrogol 4000 - for the treatment of hypertension. treatment should not be initiated with this fixed-dose combination.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - rifampicin, quantity: 300 mg - capsule - excipient ingredients: maize starch; magnesium stearate; gelatin; erythrosine; titanium dioxide; indigo carmine - tuberculosis. in the initial treatment and in re-treatment of patients with tuberculosis, rifadin must be used in conjunction with at least one other antituberculosis drug. leprosy. in the management of lepromatous leprosy and dimorphous leprosy to effect speedy conversion of the infectious state to the noninfectious state, which may be expected to occur in 3 to 4 months of treatment. as an alterantive drug in lepromatous, dimorphous, indeterminate and tuberculoid leprosy resistant to sulfones and other antileprosy drugs. as an alternative drug in all those patients having true drug allergy to the more commonly used antileprosy drugs. meningococcal disease. prophylaxis of meningococcal disease in close contacts of known cases and in carriers. (rifadin is not indicated for the treatment of meningococcal infections). haemophilus influenzae. prophylaxis of household contacts of patients with h. influenzae type b.

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - rifampicin, quantity: 150 mg - capsule - excipient ingredients: maize starch; magnesium stearate; gelatin; erythrosine; titanium dioxide; indigo carmine - tuberculosis. in the initial treatment and in re-treatment of patients with tuberculosis, rifadin must be used in conjunction with at least one other antituberculosis drug. leprosy. in the management of lepromatous leprosy and dimorphous leprosy to effect speedy conversion of the infectious state to the noninfectious state, which may be expected to occur in 3 to 4 months of treatment. as an alterantive drug in lepromatous, dimorphous, indeterminate and tuberculoid leprosy resistant to sulfones and other antileprosy drugs. as an alternative drug in all those patients having true drug allergy to the more commonly used antileprosy drugs. meningococcal disease. prophylaxis of meningococcal disease in close contacts of known cases and in carriers. (rifadin is not indicated for the treatment of meningococcal infections). haemophilus influenzae. prophylaxis of household contacts of patients with h. influenzae type b.